Intraventricular Hemorrhage
Conditions
Brief summary
Intraventricular hemorrhage (IVH) is a leading cause of brain injury in infants born before term. Severe IVH, which occurs nearly exclusively in very preterm infants (born before 32 weeks gestation) who are already at risk of neurodevelopmental delays and cerebral palsy at baseline, results in a \ 5 times higher risk of death or moderate-severe neurodevelopmental impairment, as well as short-term morbidities in the neonatal intensive care unit (NICU). Infants with grade I and II IVH, although less severe than the higher grades of IVH, also have a higher risk of death or moderate to severe neurodevelopmental impairment compared to infants with a normal head ultrasound. Outcomes are worsened by the fact that the brains of these preterm infants are not fully developed, so the progenitor cells that would later differentiate and mature are damaged, resulting in hypomyelination and gray matter loss that are associated with poor neurodevelopmental outcomes. There is no available therapy to treat the IVH or resultant brain injury, other than symptomatic management for resultant post-hemorrhagic hydrocephalus with lumbar punctures and temporary or permanent shunts, which have significant risks on their own. This is a phase I trial to determine whether fresh intranasal human milk (HM) can be safely delivered as stem cell therapy to preterm IVH patients within a 3-hour window from HM expression and to identify signals which would indicate whether intranasal HM stimulates the repair of damaged brain tissue. Outcomes will be compared to HM fed historical IVH controls. Recruitment will take place in tertiary care NICUs in Toronto, which care for the highest proportion of very preterm infants with IVH in Canada. These NICUs have already adopted a common protocolized approach to manage severe IVH and post-hemorrhagic hydrocephalus with intensive monitoring, early symptomatic management, and detailed prospectively collected IVH data.
Interventions
OTHERHuman breast milk
Intranasal human breast milk
Sponsors
MOUNT SINAI HOSPITAL
The Hospital for Sick Children
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 33 Weeks
Healthy volunteers
No
Inclusion criteria
1\. Preterm infants (\<33 weeks gestation at birth, stratified \< and ≥28 weeks) with any grade IVH/intraparenchymal hemorrhage/infarction on head ultrasound in the first 10 days of life. Diagnostic criteria will be based on the Papile definitions as used by the study sites/Toronto Centre for Neonatal Health for PHVD management, outlined in the document Intraventricular Hemorrhage and Measurements of Lateral Ventricular Size from Head Ultrasound
Exclusion criteria
1. Disorders associated with neurodevelopmental delays or impairment (i.e. Trisomy 21) 2. Moribund/critically ill infant or known lethal diagnosis with plans by medical team to redirect care 3. Choanal atresia or anomalies that would not allow intranasal treatment 4. Surgical condition (e.g. esophageal atresia) for which team feels intranasal HM is contraindicated 5. Enrolled in other intervention trials in which primary target is neurodevelopmental outcome 6. Parent with lactation contraindication(s) (i.e. HIV) or parent who declines lactation initiation 7. Lactating parent unable to provide fresh HM: unable/unwilling to pump at study site or unable to have fresh HM delivered by designee at least once/day for 3 days within 3 hours of pumping AND located (in hospital or home) \>30km from study sites (for courier services)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as described in the protocol | 1 year | Increased respiratory support settings or increase in Fio2 by more than 10% for more than 1 hour after the intervention, need for PPV/bagging immediately (within 5 minutes) of administration, or need for escalation of respiratory modality (ie NC to CPAP or NIV to intubation) in the hour after administration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The number of participants with IVH related long-term adverse neurodevelopmental outcomes compared with a cohort of HM-fed historical controls with IVH from 30 months prior to the intervention cohort. | 2 years | Cerebral Palsy, Gross motor delay (in the absence of CP), Fine motor delay, Vision impairment (blindness or wears glasses), Hearing impairment (aided / cochlear implant), Cognitive delay, Speech and language delay |
| Interference of IHM administration with routine clinical care measured using post-intervention staff survey | 1 year | — |
| Number of participants with any grade IVH unable to be recruited within 10 days of birth | 1 year | — |
| Number of eligible patients unable to receive intranasal HM administration within 3 hours of HM collection | 1 year | — |
Other
| Measure | Time frame |
|---|---|
| Number of stem cells in maternal milk provided by lactating parents of preterm infants | 1 year |
| Number of stem cells measured in CSF of treated infants who have lumbar punctures for clinical indications. | 1 year |
Countries
Canada
Outcome results
None listed